C. B. Contributors, ;. Tb, . Tb, . Smd, C. M. Jt et al., SD: responsible for study execution and data collection. A-LC, LC and JB: Responsible for sample collection

, Hadassah France, Chancellerie des Universités de Paris (Legs POIX), and ARSMESO44. All recruited patients gave signed, informed consent. All the collected samples and the associated clinical information were registered in database, Funding This work was supported by INSERM, CNRS, the 'Institut de recherche en santé respiratoire des Pays de la Loire

, Provenance and peer review Not commissioned; externally peer reviewed. data availability statement The datasets used and analyzed during the current study are available from the corresponding author open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non

N. J. Vogelzang, J. J. Rusthoven, and J. Symanowski, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, vol.21, pp.2636-2680, 2003.

B. M. Burt, S. J. Rodig, and T. R. Tilleman, Circulating and tumorinfiltrating myeloid cells predict survival in human pleural mesothelioma, Cancer, vol.117, pp.5234-5278, 2011.

H. Ujiie, K. Kadota, and J. Nitadori, The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers, Oncoimmunology, vol.4, p.1009285, 2015.

A. Mantovani, F. Marchesi, and A. Malesci, Tumour-Associated macrophages as treatment targets in oncology, Nat Rev Clin Oncol, vol.14, pp.399-416, 2017.

R. Cornelissen, L. A. Lievense, and A. P. Maat, Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma, PLoS One, vol.9, p.106742, 2014.

R. Cornelissen, L. A. Lievense, and J. Robertus, Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma, Lung Cancer, vol.88, pp.332-339, 2015.

A. Chéné, S. Almeida, and T. Blondy, Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages, J Thorac Oncol, vol.11, pp.1765-73, 2016.

P. Jeannin, L. Paolini, and C. Adam, The roles of CSFS on the functional polarization of tumor-associated macrophages, Febs J, vol.285, pp.680-99, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01718654

M. Baghdadi, H. Endo, and Y. Tanaka, Interleukin 34, from pathogenesis to clinical applications, Cytokine, vol.99, pp.139-186, 2017.

E. D. Foucher, S. Blanchard, and L. Preisser, IL-34-and M-CSFinduced macrophages switch memory T cells into Th17 cells via membrane IL-1?, Eur J Immunol, vol.45, pp.1092-102, 2015.

F. Gueugnon, S. Leclercq, and C. Blanquart, Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011.

A. De-reyniès, M. Jaurand, and A. Renier, Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014.

R. Tranchant, L. Quetel, and A. Tallet, Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma, Clin Cancer Res, vol.23, pp.3191-202, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02478604

P. Smeele, S. M. Almeida, and C. Meiller, Brain-Derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis, Mol Cancer, vol.17, p.148, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01904612

Y. Blum, C. Meiller, and L. Quetel, Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications, Nat Commun, vol.10, p.1333, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02090279

D. Coulais, C. Panterne, and J. Fonteneau, Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads, Cytotherapy, vol.14, pp.887-96, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02446857

D. Roulois, V. Vignard, and F. Gueugnon, Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells, Eur Respir J, vol.38, pp.1117-1143, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02483736

E. Becht, A. De-reyniès, and N. A. Giraldo, Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy, Clin Cancer Res, vol.22, pp.4057-66, 2016.

L. A. Lievense, R. Cornelissen, and K. Bezemer, Pleural effusion of patients with malignant mesothelioma induces macrophagemediated T cell suppression, J Thorac Oncol, vol.11, pp.1755-64, 2016.

D. Laoui, E. Van-overmeire, D. Baetselier, and P. , Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression, Front Immunol, vol.5, p.489, 2014.

J. A. Hamilton, A. D. Cook, and P. P. Tak, Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases, Nat Rev Drug Discov, vol.16, pp.53-70, 2016.

H. Lin, E. Lee, and K. Hestir, Discovery of a cytokine and its receptor by functional screening of the extracellular proteome, Science, vol.320, pp.807-818, 2008.

B. Wang, W. Xu, and M. Tan, Integrative genomic analyses of a novel cytokine, interleukin-34 and its potential role in cancer prediction, Int J Mol Med, vol.35, pp.92-102, 2015.

S. Zhou, Z. Hu, and Z. Zhou, miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis, Hepatology, vol.63, pp.1560-75, 2016.

K. Zins, G. Heller, and M. Mayerhofer, Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes, Oncotarget, vol.9, pp.23126-23174, 2018.

M. Baghdadi, H. Wada, and S. Nakanishi, Chemotherapy-Induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells, Cancer Res, vol.76, pp.6030-6072, 2016.

M. Cioce, C. Canino, and C. Goparaju, Autocrine CSF-1R signaling drives mesothelioma chemoresistance via Akt activation, Cell Death Dis, vol.5, p.1167, 2014.

M. Li, Y. Dong, and Z. Chen, Microrna-31 negatively regulates interleukin-34 expression in vitro, Immunol Invest, vol.48, pp.1-11, 2019.

A. Truini, S. Coco, and C. Genova, Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma, Microrna, vol.5, pp.12-18, 2016.

S. V. Ivanov, C. Goparaju, and P. Lopez, Pro-Tumorigenic effects of miR-31 loss in mesothelioma, J Biol Chem, vol.285, pp.22809-22826, 2010.

S. Matsumoto, K. Nabeshima, and M. Hamasaki, Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component, Med Oncol, vol.31, p.303, 2014.

H. L. Moody, M. J. Lind, and S. G. Maher, Microrna-31 regulates chemosensitivity in malignant pleural mesothelioma, Mol Ther Nucleic Acids, vol.8, pp.317-346, 2017.

J. M. Brown, L. Recht, and S. Strober, The promise of targeting macrophages in cancer therapy, Clin Cancer Res, vol.23, pp.3241-50, 2017.

C. H. Ries, M. A. Cannarile, and S. Hoves, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, vol.25, pp.846-59, 2014.

F. Dammeijer, L. A. Lievense, and M. E. Kaijen-lambers, Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy, Cancer Immunol Res, vol.5, pp.535-581, 2017.